Iluzanebart is under clinical development by Vigil Neuroscience and currently in Phase III for Neurodegenerative Diseases. According to GlobalData, Phase III drugs for Neurodegenerative Diseases have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Iluzanebart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Iluzanebart overview

VGL-101 is under development for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), Alzheimer's disease, unspecified neurologic disorders and cerebral adrenoleukodystrophy (cALD). It is administered through parenteral and intravenous route of administration. It is a fully human monoclonal antibody agonist targeting the triggering receptor expressed on myeloid cells 2 (TREM2).

Vigil Neuroscience overview

Vigil Neuroscience is a biotechnology company that discovers and develops microglial therapeutics for the treatment of neurodegenerative diseases. The company is investigating its lead candidate VGL101, a fully human monoclonal antibody for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), cerebral adrenoleukodystrophy (cALD) and Alzheimer’s disease. It is also evaluating small molecule term2 agonist, a microglial receptor protein targeting microangiopathies and Alzheimer’s disease. Vigil Neuroscience utilizes modern neuroscience drug development tools to develop precision-based therapies. The company works in collaboration with academic organizations, and pharmaceutical and biotechnology companies to develop its products. Vigil Neuroscience is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Iluzanebart’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.